To evaluate the therapeutic efficacy of simultaneously blocking VEGF-B and IL-17A signaling, their neutralizing antibodies anti-VEGF-B and anti-IL-17A were employed to explore their roles in improving renal function and alleviating renal damage in the DKD mouse model which is widely used [25]. This evidence concerns the gene IL17A and diabetic kidney disease.